Login to Your Account



Clinic Roundup


Wednesday, February 8, 2012
• Anacor Pharmaceuticals Inc., of Palo Alto, Calif., said it plans to focus on developing AN2728 for atopic dermatitis in 2012 and will defer the start of a planned Phase III trial in psoriasis, which was being designed under a special protocol assessment. The decision was based on the higher unmet need in atopic dermatitis and recent positive data from a Phase IIa atopic dermatitis trial. Anacor also released positive preliminary data from two safety studies of AN2728, showing it is well tolerated when applied to large body surface areas and sensitive skin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription